Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sigma Healthcare Limited (SIG.AX)
AUD2.93
+0.01 (+0.34%)
AU ASX Healthcare Medical - Distribution
Address
3 Myer Place 3178
Clayton, VIC, AU
Clayton, VIC, AU
CEO
Vikesh Ramsunder
Website
sigmahealthcare.com.au
IPO
2000-01-03
ISIN AU000000SIG5
Description
Sigma Healthcare Limited, together with its various operating divisions, primarily engages in the wholesale supply and distribution of pharmaceutical goods across Australia. The company also manages a significant network of approximately 1,200 retail pharmacies, encompassing both independent outlets and prominent brands such as Amcal, Discount Drug Stores, Guardian, WholeLife, and PharmaSave. Beyond retail, its comprehensive service portfolio includes wholesale provisions for hospital pharmacies, as well as crucial dose administration aid services delivered to the aged care sector, community pharmacies, and directly to individuals in their homes. Furthermore, Sigma offers advanced technology solutions and data analytics, alongside product development and support for its range of private and exclusive label products. It is also a key supplier of medical consumables and devices to a broad spectrum of customers, from pharmacies and aged care facilities to hospitals and clinics. In addition, the company provides contract logistics services to pharmaceutical manufacturers and other supply partners. Established in 1912, Sigma Healthcare Limited maintains its corporate headquarters in Rowville, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD2.93
+0.01 (+0.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15M
Beta
0.34
Float Shares
5.07B
Free Float %
43.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.80% | +3.16% | +5.38% | +3.52% | +2.08% | +0.00% | -2.65% | +410.91% | +439.99% | +169.72% | +9.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.93
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | +1 |
| Buy | 8 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
7.15
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%+47.3% ★ Q4'25: +227.5% (vs Q3'23)
-
EPS growth Medical - Distribution: +4.9%-309.5% Q4'25: +208.4% (vs Q3'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-6.8% Q4'25: +5.3% (vs Q3'23)
-
EBIT margin Medical - Distribution: +3.0%+0.6% Q4'25: +9.9% (vs Q3'23)
-
ROIC Medical - Distribution: +5.7%+1.9% Q4'25: +19.8% (vs Q3'23)
-
Share dilution Medical - Distribution: +0.0%+47.8% Q4'25: +994.0% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×2.38× Q4'25: 1.30× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jan 2006 actual |
Jan 2007 actual |
Jan 2008 actual |
Jan 2009 actual |
Jan 2010 actual |
Jan 2011 actual |
Jan 2012 actual |
Jan 2013 actual |
Jan 2014 actual |
Jan 2015 actual |
Jan 2016 actual |
Jan 2017 actual |
Jan 2018 actual |
Jan 2019 actual |
Jan 2020 actual |
Jan 2021 actual |
Jan 2022 actual |
Jan 2023 actual |
Jan 2024 actual |
Jan 2025 actual |
Jan 2026 15 Rev. Ana. 12 EPS Ana. |
Jan 2027 15 Rev. Ana. 12 EPS Ana. |
Jan 2028 14 Rev. Ana. 9 EPS Ana. |
Jan 2029 7 Rev. Ana. 3 EPS Ana. |
Jan 2030 7 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.19B
est: 2.23B (-1.6%)
|
2.73B
est: 2.74B (-0.2%)
|
2.99B
est: 3.07B (-2.5%)
|
3.11B
est: 3.19B (-2.5%)
|
3.26B
est: 3.29B (-0.8%)
|
2.94B
est: 3.43B (-14.2%)
|
2.88B
est: 2.93B (-1.9%)
|
2.97B
est: 2.97B (-0.1%)
|
2.97B
est: 3.07B (-3.0%)
|
3.14B
est: 3.14B (+0.0%)
|
3.46B
est: 3.42B (+1.1%)
|
4.37B
est: 4.39B (-0.5%)
|
4.09B
est: 4.17B (-1.9%)
|
3.98B
est: 4.08B (-2.5%)
|
3.24B
est: 3.15B (+2.9%)
|
3.40B
est: 3.48B (-2.3%)
|
3.45B
est: 3.45B (+0.0%)
|
3.66B
est: 3.66B (+0.0%)
|
3.32B
est: 3.32B (+0.0%)
|
4.89B
est: 4.57B (+7.0%)
|
10.82B
10.59B – 11.00B
+136.6% YoY
|
12.07B
11.33B – 12.58B
+11.5% YoY
|
13.28B
13.26B – 13.29B
+10.0% YoY
|
15.02B
14.38B – 15.46B
+13.1% YoY
|
16.44B
15.75B – 16.93B
+9.5% YoY
|
| EBITDA |
146.28M
est: 31.28M (+367.7%)
|
168.89M
est: 92.87M (+81.9%)
|
159.94M
est: 113.22M (+41.3%)
|
236.23M
est: 62.68M (+276.9%)
|
-262.35M
est: 37.98M (-790.7%)
|
-3.87M
est: -464.36M (+99.2%)
|
82.94M
est: -285.72M (+129.0%)
|
32.93M
est: 73.38M (-55.1%)
|
76.57M
est: 27.53M (+178.1%)
|
83.96M
est: 70.11M (+19.8%)
|
92.02M
est: 78.39M (+17.4%)
|
90.98M
est: 91.13M (-0.2%)
|
93.09M
est: 70.55M (+31.9%)
|
77.33M
est: 71.25M (+8.5%)
|
24.94M
est: 30.64M (-18.6%)
|
68.96M
est: -31.83M (+316.6%)
|
30.23M
est: -33.15M (+191.2%)
|
50.21M
est: -34.55M (+245.3%)
|
53.25M
est: 46.60M (+14.3%)
|
55.47M
est: 63.45M (-12.6%)
|
151.78M
148.50M – 154.22M
+139.2% YoY
|
169.26M
158.94M – 176.40M
+11.5% YoY
|
186.20M
185.95M – 186.46M
+10.0% YoY
|
210.60M
201.69M – 216.88M
+13.1% YoY
|
230.63M
220.87M – 237.51M
+9.5% YoY
|
| EBIT |
125.37M
est: 14.10M (+789.5%)
|
168.89M
est: 153.68M (+9.9%)
|
159.94M
est: 188.56M (-15.2%)
|
191.46M
est: 164.59M (+16.3%)
|
-308.17M
est: 196.42M (-256.9%)
|
-8.08M
est: -316.61M (+97.4%)
|
77.43M
est: -7.91M (+1,079.4%)
|
27.27M
est: 71.25M (-61.7%)
|
70.32M
est: 23.82M (+195.2%)
|
78.20M
est: 74.34M (+5.2%)
|
82.26M
est: 83.67M (-1.7%)
|
82.69M
est: 99.12M (-16.6%)
|
85.21M
est: 79.26M (+7.5%)
|
63.80M
est: 81.29M (-21.5%)
|
-2.32M
est: 47.84M (-104.8%)
|
40.38M
est: -3.32M (+1,316.6%)
|
2.53M
est: -3.46M (+173.3%)
|
19.87M
est: -3.60M (+651.5%)
|
24.93M
est: 21.00M (+18.7%)
|
29.66M
est: 28.59M (+3.7%)
|
68.40M
66.92M – 69.50M
+139.2% YoY
|
76.28M
71.62M – 79.49M
+11.5% YoY
|
83.91M
83.79M – 84.02M
+10.0% YoY
|
94.91M
90.89M – 97.74M
+13.1% YoY
|
103.93M
99.53M – 107.03M
+9.5% YoY
|
| Net Income |
104.85M
est: 163.80M (-36.0%)
|
101.79M
est: 128.74M (-20.9%)
|
77.15M
est: 114.12M (-32.4%)
|
80.12M
est: 80.11M (+0.0%)
|
-389.04M
est: 82.67M (-570.6%)
|
-235.38M
est: -398.58M (+40.9%)
|
49.17M
est: -204.49M (+124.0%)
|
18.69M
est: 49.86M (-62.5%)
|
53.54M
est: 19.28M (+177.6%)
|
52.77M
est: 56.58M (-6.7%)
|
50.50M
est: 56.57M (-10.7%)
|
53.18M
est: 62.52M (-14.9%)
|
55.06M
est: 52.07M (+5.7%)
|
36.52M
est: 53.45M (-31.7%)
|
-12.33M
est: 27.72M (-144.5%)
|
43.53M
est: -13.38M (+425.2%)
|
-7.24M
est: -13.94M (+48.1%)
|
1.81M
est: 14.53M (-87.5%)
|
4.51M
est: 6.24M (-27.7%)
|
-13.84M
est: 59.65M (-123.2%)
|
102.88M
94.97M – 110.80M
+72.5% YoY
|
119.00M
110.71M – 127.30M
+15.7% YoY
|
143.33M
127.41M – 159.25M
+20.4% YoY
|
179.17M
169.31M – 186.11M
+25.0% YoY
|
205.88M
194.55M – 213.87M
+14.9% YoY
|
| SGA |
172.55M
est: 179.95M (-4.1%)
|
203.68M
est: 212.03M (-3.9%)
|
207.98M
est: 228.36M (-8.9%)
|
223.17M
est: 215.85M (+3.4%)
|
247.18M
est: 230.37M (+7.3%)
|
158.13M
est: 244.99M (-35.5%)
|
170.58M
est: 132.65M (+28.6%)
|
169.20M
est: 172.90M (-2.1%)
|
180.21M
est: 174.48M (+3.3%)
|
201.29M
est: 198.39M (+1.5%)
|
235.86M
est: 215.77M (+9.3%)
|
257.75M
est: 292.00M (-11.7%)
|
275.01M
est: 260.51M (+5.6%)
|
296.10M
est: 266.95M (+10.9%)
|
288.74M
est: 224.76M (+28.5%)
|
309.00M
est: 313.62M (-1.5%)
|
309.60M
est: 326.66M (-5.2%)
|
293.00M
est: 340.39M (-13.9%)
|
261.77M
est: 268.08M (-2.4%)
|
312.85M
est: 367.65M (-14.9%)
|
873.22M
854.37M – 887.27M
+137.5% YoY
|
973.79M
914.39M – 1.01B
+11.5% YoY
|
1.07B
1.07B – 1.07B
+10.0% YoY
|
1.21B
1.16B – 1.25B
+13.1% YoY
|
1.33B
1.27B – 1.37B
+9.5% YoY
|
| EPS |
0.07
est: 0.10 (-35.9%)
|
0.06
est: 0.11 (-42.4%)
|
0.05
est: 0.09 (-48.1%)
|
0.05
est: 0.10 (-47.8%)
|
-0.39
est: 0.09 (-558.0%)
|
-0.20
est: 0.04 (-586.9%)
|
0.04
est: 0.05 (-11.6%)
|
0.02
est: 0.05 (-65.6%)
|
0.05
est: 0.04 (+20.1%)
|
0.03
est: 0.05 (-28.8%)
|
0.05
est: 0.05 (-8.4%)
|
0.03
est: 0.06 (-42.5%)
|
0.05
est: 0.05 (-2.6%)
|
0.04
est: 0.04 (-10.9%)
|
-0.01
est: 0.01 (-204.5%)
|
0.04
est: 0.03 (+56.3%)
|
-0.01
est: -0.01 (-4.6%)
|
0.00
est: 0.00 (-7.2%)
|
0.00
est: 0.00 (+10.0%)
|
-0.01
est: 0.04 (-123.0%)
|
0.06
0.06 – 0.07
+69.4% YoY
|
0.08
0.07 – 0.08
+19.0% YoY
|
0.09
0.08 – 0.10
+16.1% YoY
|
0.11
0.11 – 0.12
+27.3% YoY
|
0.13
0.12 – 0.14
+14.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
374.89M
OE per share TTM
-0.06
Owner's Yield
1.11%
Maintenance CapEx ratio
68.08%
Maint CapEx / Avg PPE
7.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 240 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Bancreek Global Select ETF BCGS | 3.14% | 1.19M | 0.80% |
| 2 | Bancreek International Large Cap ETF BCIL | 3.14% | 950.3K | 0.80% |
| 3 | VanEck - MSCI Australian Sustainable Equity ETF GRNV.AX | 2.07% | 3.38M | 0.35% |
| 4 | BetaShares - Australian Ex-20 Portfolio Diversifier ETF EX20.AX | 1.50% | 6.89M | 0.25% |
| 5 | VanEck - Australian Equal Weight ETF MVW.AX | 1.42% | 31.46M | 0.35% |
| 6 | BetaShares - Geared Australian Equities Complex ETF GEAR.AX | 1.31% | 5.69M | 0.78% |
| 7 | Amundi MSCI Pacific Ex Japan SRI Climate Paris Aligned - UCITS ETF DR - EUR (D) APXJ.DE | 0.99% | 5.36M | 0.45% |
| 8 | Amundi MSCI Pacific Ex Japan SRI Climate Paris Aligned UCITS ETF DR - EUR (C) CP9.PA | 0.99% | 5.36M | 0.45% |
| 9 | Amundi MSCI Pacific Ex Japan SRI Climate Paris Aligned UCITS ETF DR - USD (C) CP9U.L | 0.99% | 5.37M | 0.20% |
| 10 | iShares Edge MSCI Australia Minimum Volatility ETF MVOL.AX | 0.77% | 162.4K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
190.1K
Shares Outstanding
11.54B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vikesh Ramsunder | CEO, MD & Executive Director | 3M | male |
| Mark Conway | Chief Strategy & Business Development Officer | 752.8K | male |
| Richard Murray ASIA | Chief Financial Officer | 468.4K | male |
| Mario Verrocchi | CEO of Chemist Warehouse & Executive Director | 396.9K | male |
| Danielle Di Pilla | Chief People Officer & Executive Director | 277.3K | female |
| Mario Tascone | Deputy CEO of Retail | — | male |
| Kara McGowan | General Counsel & Chief Legal Officer and Company Secretary | — | female |
| Gary Woodford | Head of Corporate Affairs | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIG.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
